Winner Medical Co., Ltd. (SHE:300888)
China · Delayed Price · Currency is CNY 28.48
+0.24 (0.85%)
Sep 14, 2026, 3:04 PM CST
Winner Medical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 16,374 | 22,035 | 24,504 | 21,889 | 30,011 | 35,164 | |
Market Cap Growth | -28.29% | -10.08% | 11.95% | -27.06% | -14.65% | -50.33% |
Enterprise Value | 14,363 | 21,718 | 22,177 | 16,936 | 25,711 | 28,699 |
Last Close Price | 28.48 | 36.83 | 40.31 | 34.59 | 45.91 | 52.14 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 20.98 | 28.69 | 35.24 | 37.71 | 18.18 | 28.37 |
Forward PE | 17.37 | 19.21 | 26.38 | 11.53 | 18.04 | 17.13 |
PS Ratio | 1.47 | 2.01 | 2.73 | 2.67 | 2.64 | 4.38 |
PB Ratio | 1.31 | 1.79 | 2.06 | 1.81 | 2.46 | 3.29 |
P/TBV Ratio | 1.70 | 2.33 | 2.78 | 2.26 | 3.11 | 3.38 |
P/FCF Ratio | 17.38 | 21.65 | 67.16 | 70.55 | 16.82 | 273.82 |
P/OCF Ratio | 9.99 | 13.23 | 19.36 | 20.59 | 10.06 | 40.34 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.29 | 1.98 | 2.47 | 2.07 | 2.27 | 3.57 |
EV/EBITDA Ratio | 7.62 | 13.47 | 19.33 | 17.06 | 12.55 | 22.43 |
EV/EBIT Ratio | 11.73 | 18.30 | 28.04 | 25.01 | 14.43 | 25.79 |
EV/FCF Ratio | 15.24 | 21.34 | 60.78 | 54.59 | 14.41 | 223.48 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.24 | 0.21 | 0.25 | 0.18 | 0.23 | 0.06 |
Debt / EBITDA Ratio | 1.58 | 1.36 | 2.12 | 1.79 | 1.25 | 0.40 |
Debt / FCF Ratio | 3.16 | 2.47 | 7.97 | 7.02 | 1.59 | 4.66 |
Net Debt / Equity Ratio | -0.23 | -0.19 | -0.15 | -0.44 | -0.51 | -0.64 |
Net Debt / EBITDA Ratio | -1.70 | -1.45 | -1.54 | -5.42 | -3.01 | -5.36 |
Net Debt / FCF Ratio | -2.99 | -2.29 | -4.84 | -17.33 | -3.46 | -53.39 |
Asset Turnover | 0.60 | 0.60 | 0.51 | 0.46 | 0.72 | 0.61 |
Inventory Turnover | 2.89 | 2.92 | 2.88 | 2.94 | 4.02 | 2.93 |
Quick Ratio | 1.39 | 1.27 | 1.13 | 2.02 | 1.88 | 4.13 |
Current Ratio | 1.88 | 1.74 | 1.53 | 2.47 | 2.21 | 4.99 |
Return on Equity (ROE) | 6.79% | 6.74% | 6.18% | 5.17% | 14.63% | 11.70% |
Return on Assets (ROA) | 4.14% | 4.03% | 2.78% | 2.39% | 7.07% | 5.29% |
Return on Invested Capital (ROIC) | 9.32% | 9.19% | 7.66% | 8.90% | 31.54% | 30.59% |
Return on Capital Employed (ROCE) | 8.90% | 8.80% | 6.00% | 5.30% | 14.00% | 9.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.82% | 3.48% | 2.84% | 2.65% | 5.50% | 3.52% |
FCF Yield | 5.75% | 4.62% | 1.49% | 1.42% | 5.95% | 0.36% |
Dividend Yield | 2.53% | 2.04% | 1.61% | 1.45% | 2.96% | 1.73% |
Payout Ratio | 56.34% | 79.02% | 59.34% | 141.56% | 24.29% | 61.98% |
Buyback Yield / Dilution | 0.23% | 0.44% | 1.33% | -0.10% | 0.77% | -9.42% |
Total Shareholder Return | 2.77% | 2.47% | 2.95% | 1.35% | 3.72% | -7.69% |